MOTS-C 10 mg

DRAGON PHARMA MOTS-C

Dragon Pharma MOTS-C 10mg represents a groundbreaking advancement in metabolic optimization technology, delivering the first mitochondrial-derived peptide with systemic regulatory functions. Discovered in 2015 by researchers at USC, MOTS-C (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA that translocates to the nucleus to regulate gene expression. This 10mg pharmaceutical-grade formulation is specifically engineered for athletes, bodybuilders, and performance enthusiasts seeking to enhance metabolic flexibility, preserve lean muscle during calorie restriction, improve exercise endurance, and combat age-related metabolic decline. By targeting the fundamental intersection of mitochondrial function and nuclear gene regulation, MOTS-C offers a unique approach to performance enhancement that transcends traditional peptide therapeutics.

DRUG COMPOSITION

Each 2mL vial contains 10mg of MOTS-C (Mitochondrial ORF of the Twelve S rRNA type-c), a 16-amino-acid peptide with the sequence: H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH. The molecular formula is C₉₇H₁₄₇N₂₉O₂₆S₂ with a molecular weight of 2178.55 g/mol. Dragon Pharma utilizes solid-phase peptide synthesis with microwave-assisted Fmoc chemistry to produce MOTS-C with ≥98% purity verified by HPLC-MS. The lyophilized powder contains no preservatives, stabilizers, or bacterial endotoxins. Unique among peptides, MOTS-C is encoded by mitochondrial DNA (position 295 in the 12S rRNA region) rather than nuclear DNA, reflecting its ancient evolutionary origins and fundamental role in cellular energy regulation.

PHARMACEUTICAL FORM

Sterile, white to off-white lyophilized powder in a 2mL Type I borosilicate glass vial with fluoropolymer-coated bromobutyl rubber stopper and aluminum crimp seal. The powder exhibits excellent solubility in bacteriostatic water or sterile saline, dissolving completely within 45 seconds of gentle swirling to form a clear, colorless solution. Lyophilization is critical for MOTS-C stability due to its methionine-rich composition which can oxidize in solution. Each batch undergoes rigorous testing for oxidation markers, ensuring the peptide maintains its reduced, biologically active form. The 10mg concentration is optimized for effective dosing while maintaining physiological relevance to endogenous MOTS-C signaling.

PHARMACEUTICAL GROUP AND ATC CODE

MOTS-C belongs to the therapeutic category "Other alimentary tract and metabolism products" (A16AX) as a mitochondrial-derived peptide. More specifically, it represents a novel class of "mitokines" - mitochondrial-encoded signaling peptides that regulate systemic metabolism. Its ATC code would provisionally be A16AX (other alimentary tract and metabolism products). Unlike traditional peptides that target specific receptors, MOTS-C functions as a metabolic regulator that translocates to the nucleus to influence gene expression through interaction with the antioxidant response element (ARE) and regulation of the folate-methionine cycle. This places it in a unique category bridging mitochondrial function and epigenetic regulation.

PHARMACOLOGICAL PROPERTIES

MOTS-C operates through a revolutionary dual-compartment mechanism: as a mitochondrial-encoded peptide that translocates to the nucleus to regulate metabolic gene expression. Its primary action involves the folate-methionine cycle, where it upregulates AICAR transformation, leading to AMPK activation independent of cellular energy status. According to research published in Cell Metabolism, MOTS-C treatment in mice: 1) Completely prevented age-dependent and high-fat-diet-induced insulin resistance; 2) Enhanced exercise capacity by improving metabolic flexibility; 3) Promoted skeletal muscle glucose uptake through GLUT4 translocation; 4) Reduced adiposity without caloric restriction. The peptide achieves these effects by nuclear translocation and interaction with the ARE (antioxidant response element), upregulating Nrf2-mediated antioxidant pathways while simultaneously influencing one-carbon metabolism through the folate cycle. This unique mechanism enhances cellular resilience to metabolic stress while optimizing fuel utilization.

THERAPEUTICAL INDICATIONS

Dragon Pharma MOTS-C 10mg is indicated for research into:

1. Enhanced metabolic flexibility for improved athletic performance and endurance
2. Preservation of lean muscle mass during cutting phases or calorie restriction
3. Improvement of insulin sensitivity and glucose metabolism
4. Reduction of exercise-induced oxidative stress and inflammation
5. Support for healthy body composition and fat loss
6. Mitigation of age-related metabolic decline
7. Enhancement of recovery from intense training sessions
8. Potential extension of healthspan through mitochondrial-nuclear communication optimization

For bodybuilders and athletes, MOTS-C is particularly valuable during contest preparation, cutting phases, or periods of metabolic stress when maintaining muscle while reducing body fat is paramount. Its ability to enhance insulin sensitivity makes it synergistic with both bulking and cutting protocols.

DOSES AND METHOD OF ADMINISTRATION

Reconstitution: Add 1-2mL of bacteriostatic water to the 10mg vial. Gently swirl until completely dissolved—avoid vigorous shaking to prevent peptide degradation and oxidation. The resulting concentration will be 5-10mg/mL. Use immediately or refrigerate reconstituted solution for up to 7 days (though immediate use is recommended for optimal potency).

Administration Routes:

1. Subcutaneous (SC): Preferred method with good bioavailability (~70-80%) and convenient self-administration.
2. Intramuscular (IM): Faster absorption but more invasive; suitable for larger doses.
3. Intravenous (IV): Not typically used due to short half-life and no significant advantage over SC.

Dosing Protocol:

• Standard research dose: 5-10mg 2-3 times weekly
• During cutting phases: 10mg every other day for 4-8 weeks
• For metabolic optimization: 5mg twice weekly ongoing
• Athletic performance: 10mg 1-2 hours before training 2-3 times weekly
• Maximum research dose: 10mg daily (short-term only under supervision)

Inject subcutaneously in abdominal tissue, rotating sites. Effects are typically noticeable within 1-2 weeks, with optimal results after 4-6 weeks of consistent use. Timing relative to meals doesn't significantly affect absorption but taking on an empty stomach may enhance metabolic effects.

CYCLE/STACKING

MOTS-C creates powerful synergistic stacks with other Dragon Pharma products:

1. With Tesamorelin 5 mg: Tesamorelin reduces visceral fat while MOTS-C enhances insulin sensitivity and metabolic flexibility—ideal for contest preparation and physique optimization.
2. With IGF-1 LR3: IGF-1 promotes muscle growth while MOTS-C enhances the nutrient partitioning and insulin sensitivity needed to maximize IGF-1 effectiveness.
3. With Sermorelin 5 mg: Sermorelin stimulates natural GH release while MOTS-C optimizes the metabolic environment for GH action—a natural anti-aging and performance stack.
4. With GW501516 (Cardarine): Both enhance endurance and fat oxidation through different pathways (PPARδ vs. AMPK/folate cycle), creating a powerful ergogenic and body recomposition stack.
5. With L-Carnitine 500: L-Carnitine facilitates fatty acid transport into mitochondria while MOTS-C optimizes mitochondrial function and metabolic flexibility—ideal for fat loss phases.

MOTS-C also pairs exceptionally well with Clenbuterol by enhancing the metabolic efficiency of beta-2 agonist action while potentially mitigating some side effects.

POST CYCLE THERAPY

MOTS-C offers unique benefits during post-cycle recovery when metabolic function is often compromised. The hormonal fluctuations of PCT can create temporary insulin resistance, impaired nutrient partitioning, and suboptimal metabolic function—all of which threaten hard-earned muscle mass. MOTS-C addresses these challenges by: 1) Enhancing insulin sensitivity to improve nutrient uptake despite hormonal instability; 2) Activating AMPK to maintain metabolic flexibility during the transition; 3) Supporting mitochondrial efficiency when cellular energy demands are high for recovery processes; 4) Reducing inflammation that can interfere with hormonal normalization. Incorporate MOTS-C at 5-10mg twice weekly during your 4-6 week PCT protocol alongside traditional SERMs like Clomid or Nolvadex. Many users report better preservation of strength, improved recovery between workouts, and reduced fat gain during this vulnerable period when using MOTS-C as part of their PCT strategy.

SIDE EFFECTS

MOTS-C exhibits an exceptional safety profile with minimal reported adverse effects:

• Very rare (<1%): Mild injection site reactions (redness, itching, discomfort)
• Extremely rare: Transient headache or mild fatigue after initial administrations
• No reports of: Hormonal disruption, blood pressure changes, or significant gastrointestinal effects
• Theoretical concerns: Over-activation of metabolic pathways in individuals with certain mitochondrial disorders
• Laboratory findings: Possible temporary reduction in fasting glucose (desired effect in most cases)

In animal studies and limited human trials, MOTS-C has shown no toxicity even at doses significantly higher than research protocols. The peptide's endogenous origin and fundamental role in metabolic homeostasis contribute to its favorable safety profile. However, as with any bioactive peptide, individual responses may vary, and appropriate monitoring is recommended during initial use.

CONTRAINDICATIONS

While MOTS-C has broad compatibility, theoretical contraindications include:

1. Active malignancies (theoretical concern about enhancing cancer cell metabolism)
2. Severe mitochondrial disorders (e.g., MELAS, MERRF syndromes)
3. Pregnancy and lactation (insufficient safety data)
4. Concurrent use with potent AMPK activators (unless under supervision)
5. Known hypersensitivity to the peptide or its components
6. Severe hypoglycemic disorders (due to glucose-lowering effects)

Notably, MOTS-C appears safe with most performance compounds, supplements, and medications commonly used by athletes. However, individuals with diabetes or on glucose-lowering medications should monitor blood glucose closely when initiating MOTS-C.

OVERDOSE

No cases of MOTS-C overdose have been reported in the research literature. Animal studies using doses up to 50 times the human equivalent (approximately 500mg for a human) showed no acute toxicity or adverse effects. The peptide appears to have a wide therapeutic window due to its homeostatic regulatory function—it enhances metabolic efficiency rather than forcing pathological changes. In case of accidental extreme overdose, standard supportive measures are recommended. The peptide is metabolized through normal peptide degradation pathways with complete elimination within 24-48 hours. There is no known antidote or specific treatment for overdose, nor is dialysis indicated due to rapid endogenous clearance.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

1. Glucose monitoring: Individuals with diabetes or prediabetes should monitor blood glucose regularly as MOTS-C enhances insulin sensitivity and glucose uptake.
2. Metabolic disorders: Those with diagnosed mitochondrial disorders should consult healthcare providers before use.
3. Cancer screening: Appropriate cancer screening is recommended before long-term use due to theoretical concerns about metabolic enhancement.
4. Athlete considerations: MOTS-C is not a substitute for proper training, nutrition, or recovery practices—it optimizes existing metabolic function.
5. Reconstitution hygiene: Strict aseptic technique is mandatory to prevent bacterial contamination.
6. Storage compliance: Refrigeration is essential for maintaining peptide stability and preventing oxidation.
7. Realistic expectations: While powerful, MOTS-C works gradually to optimize metabolic function; dramatic immediate effects are unlikely.
8. Drug testing: MOTS-C is not banned by WADA but athletes should verify competition status with governing bodies.

INTERACTIONS WITH OTHER DRUGS

1. Metformin/other AMPK activators: Potent synergy but may require glucose monitoring to prevent hypoglycemia.
2. Insulin/sulfonylureas: Enhanced glucose-lowering effects; dose adjustment may be necessary.
3. Beta-2 agonists (Clenbuterol): May enhance metabolic effects while potentially mitigating some side effects.
4. Thyroid medications: Interesting synergy as both optimize metabolic rate through different mechanisms.
5. Anabolic compounds: Enhanced nutrient partitioning and insulin sensitivity may improve results from AAS cycles.
6. Antioxidants (NAC, glutathione): Complementary effects as MOTS-C upregulates endogenous antioxidant pathways.
7. Folate/B12 supplements: Important cofactors for MOTS-C mechanism through one-carbon metabolism.

Positive interactions include enhanced effects of endurance compounds, improved tolerance to calorie restriction, and better results from body recomposition protocols when combined with appropriate training and nutrition.

PRESENTATION, PACKAGING

Dragon Pharma MOTS-C 10mg is supplied as a single 2mL glass vial containing white lyophilized powder. Each vial is individually packaged in a sealed amber glass vial within an argon-flushed aluminum pouch to prevent oxidation. The outer box displays comprehensive product information, HPLC-MS verified purity certification, oxidation status confirmation, batch number, expiration date, and Dragon Pharma hologram for authenticity verification. Research packs of 5, 10, and 20 vials are available for extended protocols. All packaging is discreet, professional, and designed for maximum stability with oxygen absorbers and desiccants to maintain peptide integrity during shipping and storage.

STORAGE

Store unopened vials at -20°C for long-term stability (up to 2 years) or at 2-8°C (36-46°F) for short-term storage (up to 3 months). The lyophilized powder is particularly sensitive to oxidation due to methionine residues; therefore, refrigeration is mandatory. Once reconstituted, store solution at 2-8°C and use within 7 days for optimal potency. Do not freeze reconstituted solution. Protect from light and oxygen exposure at all times. Always verify solution clarity before use—discard if discolored (yellowing indicates oxidation), cloudy, or containing particles.

DELIVERY TO THE USA

Dragon Pharma ships MOTS-C 10mg discreetly to all 50 states via expedited domestic shipping with temperature-controlled packaging. Orders are processed within 24-48 hours and delivered within 2-5 business days via temperature-controlled courier services. Tracking information with temperature monitoring is provided to ensure the peptide never exceeds recommended storage temperatures during transit. Packaging is plain, professional, and unmarked for privacy. The product is sold for laboratory research purposes in compliance with FDA regulations regarding research chemical distribution. Domestic reshipping from US-based facilities ensures reliable delivery and eliminates customs scrutiny.

LEGAL STATUS

In the United States, MOTS-C is classified as a research chemical peptide, not approved by the FDA for any therapeutic indication. It falls under the regulatory framework for research peptides and is sold for laboratory research purposes only. It is not a controlled substance under the CSA. Purchasers assume full responsibility for compliance with local and federal regulations. Athletes should note that while not explicitly banned by most sports organizations, peptides may fall under general prohibitions against performance-enhancing methods. The product is labeled "For research use only. Not for human consumption." in accordance with FDA guidelines.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus
• The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis

PROFILE

• Chemical name: Mitochondrial ORF of the Twelve S rRNA type-c (16-amino acid peptide)
• Chemical formula: C₉₇H₁₄₇N₂₉O₂₆S₂
• Percentage of anabolic activity: 0% (non-hormonal metabolic regulator)
• Percentage of androgenic activity: 0% (non-androgenic)
• Active half life: 2-4 hours (plasma); metabolic effects last 24-48 hours
• Recommended dosage: 5-10mg 2-3 times weekly subcutaneously
• Acne: Not associated
• Bloating (water retention): May actually reduce inflammation-related water retention
• HBR: No hepatobiliary reactions; may improve liver metabolic function
• Hepatic toxicity: None; demonstrates hepatoprotective properties in research
• Aromatization: Does not aromatize